8.3 Hormonal Therapy

Hormonal Therapy in Cancer Treatment

Hormonal therapy treats cancers that depend on hormones to grow. It works by cutting off the hormone supply, blocking hormones from reaching cancer cells, or destroying the receptors that hormones bind to. The main cancers treated this way are breast, prostate, endometrial, and thyroid cancers.

Key Features of Hormonal Therapy Drugs

Hormone-dependent (or hormone-sensitive) cancers need hormones like estrogen or testosterone to fuel their growth. Hormonal therapy disrupts this fuel supply through three main mechanisms:

Blocking hormone production:

• Aromatase inhibitors (AIs) such as anastrozole and letrozole block the aromatase enzyme, which converts androgens into estrogen. These are used primarily in postmenopausal breast cancer because, after menopause, aromatase in peripheral tissues (especially fat) is the main source of estrogen.
• GnRH agonists/antagonists such as leuprolide and goserelin suppress the hypothalamic-pituitary-gonadal (HPG) axis. GnRH agonists initially cause a surge in hormone levels (called a "flare") before suppressing production, while GnRH antagonists suppress it immediately. Both are used to reduce testosterone in prostate cancer and estrogen in premenopausal breast cancer.

Interfering with hormone receptor binding:

• Selective estrogen receptor modulators (SERMs) like tamoxifen bind to estrogen receptors and block estrogen from activating them in breast tissue. Tamoxifen acts as an estrogen antagonist in the breast but as a partial agonist in the uterus and bone, which explains both its benefits (bone protection) and risks (endometrial cancer).
• Antiandrogens like flutamide and bicalutamide compete with testosterone and dihydrotestosterone (DHT) for binding at androgen receptors on prostate cancer cells, blocking the growth signal.

Inducing hormone receptor degradation:

• Selective estrogen receptor degraders (SERDs) like fulvestrant bind to the estrogen receptor and cause it to be broken down entirely. Unlike SERMs, SERDs eliminate the receptor rather than just blocking it, so there's no partial agonist activity in other tissues.

Clinical Applications of Hormonal Therapies

Breast cancer

• Used as adjuvant therapy in hormone receptor-positive (HR+) early-stage breast cancer to reduce recurrence risk. Tamoxifen is standard for premenopausal patients; AIs are preferred for postmenopausal patients.
• Also used in metastatic HR+ breast cancer to slow progression and improve survival.
• Common adverse effects: hot flashes, joint pain (especially with AIs), osteoporosis (with AIs), and increased risk of endometrial cancer and venous thromboembolism (with tamoxifen).

Prostate cancer

• GnRH agonists/antagonists and antiandrogens are used for advanced or metastatic prostate cancer to slow progression and relieve symptoms. This approach is sometimes called androgen deprivation therapy (ADT).
• Common adverse effects: hot flashes, sexual dysfunction, loss of muscle mass, osteoporosis, metabolic syndrome, and increased cardiovascular risk.

Endometrial cancer

• Progestins (such as megestrol acetate or medroxyprogesterone) are used for advanced or recurrent endometrial cancer to control tumor growth. These work by opposing estrogen's proliferative effects on the endometrium.
• Common adverse effects: weight gain, venous thromboembolism, and fluid retention.

Thyroid cancer

• In differentiated thyroid cancer, levothyroxine is given at doses high enough to suppress thyroid-stimulating hormone (TSH), since TSH can stimulate growth of residual thyroid cancer cells. This is TSH suppression therapy, not traditional "hormonal therapy" in the same sense as the others.
• Common adverse effects from supraphysiologic thyroid hormone doses: symptoms of hyperthyroidism (tachycardia, tremor, heat intolerance), osteoporosis with long-term use, and atrial fibrillation.

Endocrine System and Hormonal Therapy

The endocrine system produces and regulates hormones that circulate through the blood and bind to specific receptors on target cells. Steroid hormones like estrogen and testosterone are the primary targets of hormonal cancer therapy because they directly drive proliferation in hormone-sensitive tumors.

Endocrine resistance is a major clinical challenge. Over time, cancer cells can develop resistance to hormonal therapy through several mechanisms: mutations in hormone receptors, activation of alternative signaling pathways, or upregulation of growth factor receptors. When resistance develops, the oncologist may switch to a different class of hormonal agent or add targeted therapy (such as a CDK4/6 inhibitor in breast cancer).

Many hormonal therapies also cause or worsen menopausal symptoms because they reduce circulating estrogen. Hot flashes, vaginal dryness, mood changes, and bone loss are common across several drug classes. Understanding this connection helps you anticipate and manage these side effects.

Nursing Considerations for Hormonal Therapy

Patient education:

• Stress the importance of adherence. Many hormonal therapies are taken daily for 5 to 10 years (e.g., tamoxifen or AIs in breast cancer). Skipping doses reduces effectiveness.
• Discuss expected side effects upfront and provide concrete management strategies so patients know what to expect and when to call the provider.

Monitoring:

• Assess treatment response and disease progression through regular clinical exams and imaging.
• Monitor for adverse effects at each visit: hot flashes, joint pain, mood changes, signs of thromboembolism (leg swelling, sudden shortness of breath), and cardiac symptoms.
• Order and track bone density scans (DEXA) as indicated, especially for patients on AIs or long-term ADT, since both accelerate bone loss. Initiate calcium, vitamin D, or bisphosphonates as prescribed.
• For patients on tamoxifen, monitor for abnormal vaginal bleeding, which may signal endometrial changes.

Medication administration:

• Verify correct dosing and timing. Most oral agents (tamoxifen, AIs, antiandrogens) are taken once daily.
• For injectable GnRH agonists (e.g., leuprolide depot), administer on schedule (monthly or every 3 to 6 months depending on formulation). Teach self-injection technique when appropriate.
• With GnRH agonists, warn patients about the initial testosterone flare in the first 1 to 2 weeks. An antiandrogen may be co-prescribed during this period to block the flare's effects.

Collaboration with the healthcare team:

• Communicate patient-reported symptoms and concerns to the oncologist so the treatment plan can be adjusted promptly.
• Coordinate with endocrinology, gynecology, or cardiology as needed for hormone-related complications (e.g., osteoporosis management, endometrial monitoring, cardiovascular risk reduction).

Patient Education for Hormonal Treatment

Pre-treatment education:

• Explain the purpose of hormonal therapy: it controls cancer growth by removing the hormonal fuel the tumor depends on. Frame it as a long-term strategy that significantly reduces recurrence risk.
• Review the treatment schedule and expected duration. For breast cancer, this often means 5 to 10 years of daily oral medication.
• Go over common side effects and practical management tips before treatment starts, so patients aren't caught off guard.

Ongoing education and support:

• Provide written materials patients can reference at home.
• Encourage patients to report new or worsening symptoms promptly rather than waiting for the next appointment. Early reporting allows earlier intervention.
• Offer referrals to support groups or counseling services. The psychological burden of long-term cancer treatment is real, and peer support can make a significant difference.

Lifestyle modifications:

• Recommend a balanced diet rich in calcium and vitamin D, along with regular weight-bearing exercise, to protect bone health during treatment.
• For hot flash management: layered clothing, cool environments, avoiding triggers (spicy food, caffeine, alcohol), and relaxation techniques. Pharmacologic options (e.g., low-dose venlafaxine) can be discussed with the provider if non-drug strategies aren't enough.
• Address sexual health proactively. Vaginal dryness and decreased libido are common with estrogen-lowering therapies. Non-hormonal vaginal moisturizers and referrals to sexual health specialists should be offered.

Follow-up care:

• Reinforce the importance of regular follow-up visits and scheduled monitoring (labs, imaging, DEXA scans).
• Teach patients the signs and symptoms of recurrence: new lumps, unexplained pain, changes in bodily functions, or persistent unexplained symptoms.
• Encourage open communication with the care team. Patients should feel comfortable asking questions and voicing concerns at any point during treatment.